Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010, 363: 711-723.
Article
CAS
PubMed
PubMed Central
Google Scholar
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ: A randomized, double-blind, placebo controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009, 15: 5591-5598.
Article
CAS
PubMed
Google Scholar
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010, 11: 155-164.
Article
CAS
PubMed
Google Scholar
O’Day SJ, Maio M, Ciarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010, 21 (8): 1712-1717.
Article
PubMed
Google Scholar
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009, 15 (23): 7412-7420.
Article
CAS
PubMed
Google Scholar
Nishino M, Jagannathan JP, Krajewski KM, O'Regan K, Hatabu H, Shapiro G, Ramaiya NH: Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-specific and Therapy-specific Response Criteria to Complement Pitfalls of RECIST. AJR Am J Roentgenol. 2012, 198 (4): 737-745.
Article
PubMed
PubMed Central
Google Scholar
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M: Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012, 30: 2046-2054.
Article
CAS
PubMed
Google Scholar
Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS: Developing a Common Language for Tumor Response to Immunotherapy: Immune-related Response Criteria using Unidimentional measurements. Clin Cancer Res. 2013, 19 (14): 3936-3943.
Article
CAS
PubMed
PubMed Central
Google Scholar
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216.
Article
CAS
PubMed
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247.
Article
CAS
PubMed
Google Scholar
Nishino M, Jagannathan JP, Ramaiya N, Van den Abbeele AD: Revised RECIST guideline version 1.1 – What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010, 195: 281-289.
Article
PubMed
Google Scholar
Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD: New Response Evaluation Criteria in Solid Tumors (revised RECIST guideline, version 1.1) in Advanced Non–Small-Cell Lung Cancer: Comparison with the original RECIST (version 1.0) and its impact on assessment of tumor response to therapy. AJR Am J Roentgenol. 2010, 195: W221-W228.
Article
PubMed
PubMed Central
Google Scholar
Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE: Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: Comparison with RECIST 1.0. AJR Am J Roentgenol. 2013, 201 (1): W64-W71.
Article
PubMed
PubMed Central
Google Scholar
Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K: Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2010, 69: 105-109.
Article
PubMed
Google Scholar
Zacharia TT, Saini S, Halpern EF, Sumner JE: CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol. 2006, 186 (4): 1067-1070.
Article
PubMed
Google Scholar
Piatek CI, Desai BB, Wei-Tsao D, Tang R, Acosta F, Pinski JK, Dorff TB, Goldkorn A, Jadvar H, Quinn DI: RECIST 1.0 versus 1.1: Implications for trial interpretation and design in advanced prostate cancer. J Clin Oncol. 2011, 29 (suppl; abstr 2563):
Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, Qin Y, Riely GJ, Kris MG, Schwartz LH: Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009, 252: 263-272.
Article
PubMed
PubMed Central
Google Scholar
Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Van den Jänne PA, Abbeele AD, Johnson BE: CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer: Performance Characteristics of Emerging Clinical Tool. Acad Radiol. 2011, 18: 54-62.
Article
PubMed
PubMed Central
Google Scholar
Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF: Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003, 21: 2574-2582.
Article
PubMed
Google Scholar
Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003, 100: 4712-4717.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008, 105: 3005-3010.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958, 53: 457-481.
Article
Google Scholar
Lin LI: A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989, 45: 255-268.
Article
CAS
PubMed
Google Scholar